Cat. No. 4664
Biological ActivityHighly potent integrin α1β1 inhibitor (IC50 = 0.8 nM for α1β1 binding to type IV collagen). Selective for α1β1 over α2β1, αIIbβ3, αvβ3, α4β1, α5β6, α9β1 and α4β7. Inhibits FGF2-stimulated angiogenesis in the chicken chorioallantoic model. Displays antitumor efficacy in a synergistic mouse model of Lewis lung carcinoma; blocks human melanoma growth in nude mice.
(Modifications: Disulfide bridge: 1 - 10, 6 - 29, 7 - 34, 19 - 36)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Brown et al (2008) Angiostatic activity of obtustatin as α1β1 integrin inhibitor in experimental melanoma growth. Int.J.Cancer 123 2195. PMID: 18712720.
Marcinkiewicz et al (2003) Obtustatin: a potent and selective inhibitor of α1β1 integrin in vitro and angiogenesis in vivo. Cancer Res. 63 2020. PMID: 12727812.
Moreno-Murciano et al (2003) Amino acid sequence and homology modeling of obtustatin, a novel non-RGD-containing short disintegrin isolated from the venom of Vipera lebetina obtusa. Protein Sci. 12 366. PMID: 12538900.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Obtustatin from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Obtustatin, supplier, integrins, alpha1beta1, a1b1, aαnβ, potent, selective, inhibitors, inhibits, antiangiogenics, angiogenesis, Tocris Bioscience, Integrin Receptor Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and selective inhibitor of integrins αvβ3 and αvβ5SM 324405
Potent TLR7 agonistRS 09
TLR4 peptide agonist; acts as an adjuvant in vivo
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.